Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 26
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Dyne Therapeutics Inc
DYN
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$15.62
-0.15
-0.95%
Dern. MÀJ: Oct 26, 4:39 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Dyne Therapeutics Financials
Dyne Therapeutics (DYN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of $(0.97) per share from
Benzinga Newsdesk
PRO
Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 30.48 percent increase over losses of $(1.05) per share from
Benzinga Newsdesk
PRO
Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.79) by 3.18 percent. This is a 13.64 percent increase over losses of $(0.88) per share from
Benzinga Newsdesk
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.
Vandana Singh
PRO
Dyne Therapeutics Q3 EPS $(0.76) Beats $(0.85) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.85) by 11.01 percent. This is a 20.83 percent increase over losses of $(0.96) per share from
Benzinga Newsdesk
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
Avi Kapoor
